I am Moriyama. We'll now explain our financial results for the second quarter of fiscal 2025 and our outlook for fiscal 2025. On the first page, you'll find a summary of this presentation in the upper and lower sections. The upper row shows the results for the second quarter of fiscal 2025. Adjusted operating income was JPY 13 billion, a decrease of minus JPY 5.6 billion from the same period last year. In the healthcare business, adjusted operating income increased due to an increase in the number of rented home medical devices, but adjusted operating income decreased in the materials, aramid, and other businesses due to large-scale periodic maintenance and other factors. Taking this opportunity, impairment losses on fixed assets were recorded in the aramid business. The bottom row shows the forecast for fiscal 2025. Adjusted operating income is JPY 25 billion, minus JPY 10 billion compared to the previous forecast of JPY 35 billion. This was due to a delay in the recovery of business performance in materials and the transfer of the aramid paper business, among other factors. The annual dividend is planned to be JPY 50 per share. There is no change from the previous outlook. I will now begin with the second quarter financial results. As a first summary, revenue decreased by JPY 56.5 billion from the same period last year. Adjusted operating income decreased by JPY 5.6 billion. Loss attributable to owners apparent was JPY 54.8 billion due to the recording of impairment losses in the aramid business and costs of structural reforms undertaken. The figure is illustrated separately for each segment. As on the previous page, overall revenue decreased by JPY 56.5 billion, and adjusted operating income decreased by JPY 5.6 billion, mainly due to intensified competition in the area of materials and the impact of large-scale periodic maintenance. Here is a little more detail on the year-on-year comparison for the materials area. Revenue was JPY 187.6 billion, minus JPY 46.9 billion from the same period last year. Adjusted operating income decreased by minus JPY 3.3 billion from the same period last year to minus JPY 1.6 billion. As for topics, compared to the previous year, the transfer of the composites business in North America was completed on July 1, 2025, and although cost structure reforms in aramid and carbon fibers are progressing, large-scale periodic maintenance and a deteriorated sales mix have caused a decline in profits. The table below shows the status of each material by business. The aramid business has been optimizing its production volume and making progress in cost reductions and structural reforms, while lower raw material and fuel prices have contributed to the increase in earnings. On the other hand, we have seen a decline in capacity utilization, which is large-scale periodic maintenance, and we also experienced a fire in August, but we believe that the impact of this fire was negligible for the year. Sales prices have been partially reduced due to the appreciation of the euro and sales expansion in areas where competition is very intense. Such were the reasons for the decrease in profit. Sales at resin remained flat, maintaining the spread despite a slight decrease in sales volume for office equipment applications. Regarding carbon fibers, we are vigorously advancing cost structure reforms, which are contributing to increased profits. However, the decrease in profit is due to lower capacity utilization resulting from lower sales volume and lower sales prices for some applications. Compared to the previous fiscal year, the composites business is on track for an increase in profit due to the established effect of improved profitability and the elimination of the deficit resulting from the transfer of the business in North America. This is an explanation of the fibers and products converting business. Compared to the same period last year, through the second quarter, revenue was JPY 170.4 billion, a JPY 3.5 billion decrease from the same period last year, and adjusted operating income was down minus JPY 1.1 billion. The resulting amount is JPY 9 billion. Overall sales have remained strong, but the decrease in adjusted operating income is due in part to higher head office costs from sales expansion efforts. To be more precise, strong sales included textiles for North America and apparel textiles for domestic and Chinese markets. We are very good at polyester staple fibers for water treatment filters, and household merchandise have maintained a good performance, which is a factor in our profit growth. On the downside, the main factor contributing to lower profits was textiles for the Chinese market. The decrease in profit was due to a slight decrease in the advanced shipment in the previous fiscal year. The next page will be on healthcare. Revenue was JPY 68.4 billion, a decrease of minus JPY 0.9 billion from the same period last year, and adjusted operating income was JPY 7.1 billion, an increase of JPY 1.7 billion from the same period last year. The increase in profit was due to two major factors: an increase in the number of rented CPAP devices and an increase in sales volume of Ostobalo, a drug used in the treatment of osteoporosis, and continued reduction of fixed costs through business restructuring. In addition, the decrease in depreciation amortization of the impairment of sales rights for diabetes treatments last year was a factor in the increase in profit. On the other hand, factors contributing to the decline in profits included reduced sales volumes of pharmaceuticals, specifically diabetes treatments and Feburic. Additionally, the impact of drug price revisions continued to affect this fiscal year. Furthermore, increased depreciation expenses resulted from significantly introducing CPAP devices, while substantially higher usage of CPAP-related expendables also contributed to rising costs. Next is the last, other areas. Revenue was JPY 24.7 billion, a decrease of JPY 5.2 billion from the same period last year, and adjusted operating income was JPY 3.3 billion, a decrease of JPY 2.2 billion from the same period last year. Overall, sales of separators and resist solutions for lithium-ion batteries, as well as membranes for various resist solutions, have remained strong. On the other hand, there are several equity method affiliates, and the decrease in their profits is a factor resulting in adjusted operating income of JPY 3.3 billion. Next page, financial income and costs, non-recurring items year- over- year. On the left side, financial income and costs, interest expenses decreased due to progress in repayment of interest-bearing debt. On the right side, non-recurring items include impairment losses on the aramid business and losses on the sale of shares in the composites business in North America, which are minus JPY 11.1 billion. Although the financial position is compared to the previous year, total assets and liabilities decreased from the previous year due to the removal of the composites business and the business in North America, as well as impairment losses on fixed assets in the aramid business. As for the other interest-bearing debt, we can see that the amount temporarily increased at the end of June 2025, but has been optimized to the level at the end of March 2025, following the completion of the transfer of the composites business in North America. As for the cash flow position, there is an increase in operating cash flow due to improvement in working capital. Next, I will explain our outlook for fiscal 2025. Firstly, the summary is explained in two ways, compared to the previous outlook and compared to the previous fiscal year. Revenue is unchanged at JPY 860 billion, and adjusted operating income is projected at JPY 25 billion, a decrease of JPY 10 billion. Since the aramid business will undergo restructuring and impairment losses, we expect profit loss attributable to owners apparent to decrease by JPY 22 billion to minus JPY 10 billion. The annual dividend per share remains unchanged at JPY 50 per share. The following figure shows a breakdown by segment. Revenue remains unchanged at JPY 860 billion, and adjusted operating income is JPY 25 billion. This JPY 25 billion minus JPY 10 billion is shown in the column on the right. The minus JPY 5 billion represents the decrease in earnings from materials. There was a positive effect from reduced depreciation expenses due to impairment. However, for aramid, the sharp depreciation of the euro, decline in capacity utilization, and revaluation of inventory value resulted in a minus JPY 5 billion. Carbon fibers, minus JPY 5 billion due to a decrease in sales volume for aircraft and industrial applications. In others, minus JPY 3 billion due to the transfer of the aramid paper business. The elimination and corporate figure was minus JPY 2 billion due to an increase in expenses for various projects that are in progress. The table on the next page shows the comparison to the previous fiscal year. Revenue decreased by about JPY 150 billion- JPY 860 billion due to the transfer of the composites business in North America. Adjusted operating income declined by JPY 2.6 billion. I've shown a little more by segment here, and as I mentioned earlier, revenue was down due to the transfer of the composites business in North America. As for adjusted operating income, healthcare increased profit, partly due to an increase in the number of rented CPAP devices, etc. However, overall profit decreased due to intensified competition in the materials, the impact of large-scale periodic maintenance, and the transfer of the aramid paper business, etc. Let me elaborate a bit more on the adjusted operating income by segment. In the materials area, revenue was JPY 330 billion, a decrease of JPY 129.3 billion from the previous fiscal year, and adjusted operating income was JPY 3 billion, a decrease of minus JPY 3 billion from the previous fiscal year. As for aramid, the explanation below overlaps with the previous one, but there are factors for an increase in profit due to progress in cost structure reforms, a decrease in depreciation amortization due to impairment losses, and an increase in sales volume. The volume of sales has been secured through various efforts, which is the reason for the increase in profit. On the other hand, the sales price has been decreasing slightly due to the appreciation of the euro, sales expansion, and other factors. The decrease in profit was also due to lower capacity utilization caused by large-scale periodic maintenance. The resin is the same as described earlier. For carbon fibers, production optimization continues to be optimized, and cost structure reform is a factor for profit increase. However, a decline in sales volume has reduced capacity utilization, which is a factor in lower profits. In the composites business, the elimination of the deficit following the completion of the transfer of the business in North America was a factor in the increase in earnings. As for fibers and products converting, the explanation is similar to the previous one, but overall sales volume is expected to be firm and profits on a par with the previous fiscal year. Revenue was JPY 350 billion, a decrease of JPY 1.9 billion from the previous fiscal year. Adjusted operating income was JPY 18 billion, an increase of JPY 200 million from the previous fiscal year. Almost the same, but we expect adjusted operating income of JPY 18 billion. The explanation for the increase in profit is that industrial materials and water treatment filters are performing well, while the explanation for the decrease in profit is that textiles for China are slightly decreasing. In healthcare, revenue was JPY 135 billion, a decrease of JPY 2 billion compared to the previous fiscal year. Adjusted operating income is expected to increase by JPY 6.8 billion- JPY 12.5 billion. The increase in profit was due to an increase in the number of rented CPAP devices and the sales volume of Ostobalo. We are strongly promoting business restructuring, so we are reducing fixed costs. The decrease in depreciation amortization is the main reason for the increase. As for the reasons for the decrease in profit, the sales volume of pharmaceuticals is still decreasing. Although the impact of the drug price revisions is expected to have a negative impact of approximately JPY 1.5 billion for the year, we are forecasting adjusted operating income of JPY 12.5 billion. Finally, other areas. As explained earlier, sales of separators and membranes have remained strong. As such, revenue was JPY 45 billion, a decrease of JPY 12.3 billion from the previous fiscal year. Adjusted operating income is JPY 1.5 billion, a decrease of JPY 5.6 billion. One of the reasons for this decrease is that we have several equity method affiliates, and we expect a decrease in profits at some of them of JPY 1.5 billion. This concludes my explanation. Next, Uchikawa will explain our initiatives for the next medium-term management plan. First, let me explain that we are currently working on two measures. First, I'll explain the second. As Uchikawa just explained, the profitability of the aramid business and the carbon fibers business is declining. In light of the above, we believe that it is very important to further advance cost structure reforms in light of changes in the external environment in order to stabilize our earnings, and we have been promoting these reforms since the beginning of the fiscal year. We will continue to implement drastic cost reductions by optimizing our production system. We will use this as the basis for making great strides during the period of the next medium-term management plan. As for how we will grow, the development of the customer-centric business model, which is described in the upper part of this report, will be our main focus, or at least we would like to make it our main focus. Until now, the company has tended to see growth somewhat in isolated pockets. Our current management team is prioritizing areas where we can leverage our strengths. This involves accelerating the customer-centric business model, specifically downstream shift, capture of peripheral markets, and participating in industry consolidation. Through these efforts, we are shifting our core focus toward building a business model that progressively solves customer challenges, moving away from the traditional model of selling individual materials or products. As explained, this initiative has been underway since the beginning of the fiscal year. We are currently prioritizing resource allocation for it. We are unable to provide details today. However, several collaborative initiatives with other companies are now taking shape. We plan to prepare these sequentially for the next medium-term management plan announcement and report them to you. Regarding each business segment, in the materials segment, we are optimizing production systems for the aramid and carbon fibers businesses mentioned earlier to enhance profitability. Previously, our strategy focused on maintaining high market share across all segments. However, we now intend to make concentration on high value-added areas one of our key pillars. In the areas we've decided to prioritize, we intend to advance the creation of new businesses that originate from customer needs. This aligns with what is written on the left, one, two, and three. In the fibers and products converting business, where we are already promoting the customer-centric business, our preparation for the future is to pursue further expansion of this business. Furthermore, in healthcare, the home healthcare business model has already shifted toward providing services to patients. We aim to advance this further by focusing on the field of intractable and rare diseases. This allows us to concentrate on an area where we can leverage the business foundation cultivated through our core strengths in home medical care. We intend to accelerate the transformation of this business. By adding the optimization of the production system for aramid and carbon fibers to these three pillars, we hope to build a base on which we can make a leap forward during the next medium-term management plan period. These are the core of our efforts to develop a medium-term management plan and to move forward into the next period. However, as I just mentioned, profitability has significantly declined, particularly in aramid and carbon fibers. Therefore, I would like to summarize and explain here what we are doing about these issues, focusing primarily on aramid. In 2022- 2023, we had a fire at our aramid raw materials plant, and natural gas prices in Europe rose abnormally due to the conflict in Ukraine. Furthermore, due to the spread of COVID-19 and other factors, it has become extremely difficult to secure workforce in Europe that can work three shifts at a fixed time in place. We have taken various measures to resolve these issues, and as previously reported, we have succeeded in achieving most of the goals as planned. On the other hand, we had promised to make this even more robust from this fiscal 2024 to the next medium-term management plan period. In the midst of this, we had to deal with a second small fire. In addition, the appreciation of the Euro and the fact that our competitors are increasing their production capacity have caused an imbalance in the supply-demand balance. The current situation is that we are promoting fundamental cost structure reforms to address these issues. This review of the production system will entail a reduction in fixed costs, and we are currently working to cut costs by approximately JPY 15 billion by reducing the workforce by more than 400 people, among other measures. Once we have achieved full realization of these goals, as I mentioned earlier, we will build a base for rapid progress by concentrating on high value-added areas, and we will further solidify this by collaborating with external partners to create new business based on customer needs, which will be carried out in parallel with these efforts. At the same time, new applications for aramid and carbon are still being developed, and many new uses will emerge where the value of the material can be fully utilized. One is that a very good amount of cable laying for transporting electricity across the seabed is expected in the future. For these, we hope to capture market growth by properly fitting our materials. Aramid, which has been affected by external factors or has lost its profitability due to internal weaknesses, and additionally our carbon fibers business. Through addressing these factors, we aim to make tangible progress toward returning to a high profitability structure within this fiscal year, bringing the situation to a point where everyone can see that we have hit bottom. These are the progress of our efforts toward the next medium-term management plan. As for returns to our shareholders who support us, we have fallen into a deficit in the current fiscal year, but we believe that the impairment losses of the aramid business are a temporary factor that occurred in 2025. In addition, as we have always followed a policy of paying stable and continuous dividends, we intend to maintain the annual dividend of JPY 50 per share for this year as well. That concludes my explanation.